Briefing
ESMO prostate guideline recommends BRCA1, BRCA2, CDK12, and PALB2 testing in CRPC
The ESMO clinical practice guideline on advanced and metastatic prostate cancer, approved by the ESMO Guidelines Committee in January 2026, recommends genomic testing for BRCA1, BRCA2, CDK12, and PALB2 in all patients with castration-resistant prostate cancer, ideally before the first treatment for metastatic CRPC.